Study yields positive results for radiopharmaceutical

12/21/2009 | MarketWire

A Phase I trial of Bryan Oncor's drug candidate for advanced lung cancer showed that it is well-tolerated and has the potential to target somatostatin receptors on tumors. Re-88 P2045 combines a synthetic peptide molecule called P2045 for the targeting of the overexpressed SSTRs and the Re-188 radioactive isotope for eliminating cancerous cells. The treatment also reduces patients' toxicity risk by allowing imaging to pinpoint those who would most likely benefit from the treatment and concentrating the dose on the tumor area.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI